| Literature DB >> 35520063 |
Peng Luo1,2, Wanxing Wei1, Saqlain Haider3, Shabana I Khan3, Mei Wang3, Weigao Pan1,2, Amar G Chittiboyina3.
Abstract
Using flavonoids and dichlone as substrates, benzonaphthofuroquinones (1, 2, 3, 5, 6, novel; 4 new) and benzoylnaphthindolizinediones (7, 8, known; 9, new) were synthesized through common base-catalyzed method and a new method of combining base-catalyzed with O2/H2O exposing. The possible reaction mechanisms may involve the process like isomerization, hydration, oxidation, decomposition and intermolecular condensation. Benzonaphthofuroquinones (2, 3, 4, 5) were found to exhibit potent cytotoxicity against carcinoma cell lines and low toxicity to normal cell lines. The compounds 4 and 5 not only expressed a significant late-stage-apoptosis against human leukemia and melanoma, but also promoted the cleavage of caspase-3 and PARP in human leukemia, which suggested that the late-stage-apoptosis and caspase-3 pathway may be responsible for the cytotoxicities of these benzonaphthofuroquinones. The replacement of the furan ring with pyrrole system in benzoylnaphthindolizinediones (7, 8, 9) resulted in the loss of anticancer activity. This journal is © The Royal Society of Chemistry.Entities:
Year: 2020 PMID: 35520063 PMCID: PMC9055798 DOI: 10.1039/d0ra06043g
Source DB: PubMed Journal: RSC Adv ISSN: 2046-2069 Impact factor: 4.036
Scheme 1The reported dunnione analogs with cytotoxicity.
Scheme 2The reported synthetic methods for benzo- or naphthanaphthofuroquinones.
Scheme 3The reported synthetic methods for benzoylnaphthindolizinediones.
Scheme 4Synthesis of benzonaphthofuroquinones and the possible reaction mechanism of 4. Reagents and conditions: (1) pyridine, 85 °C, 24 h; (2) pyridine, moist air (O2/H2O) injection, 85 °C, 24 h.
Scheme 5Synthesis of benzoylnaphthindolizinediones and the possible reaction mechanisms. Reagents and conditions: pyridine, moist air (O2/H2O) injection, 85 °C, 24 h.
Cytotoxicities against carcinoma and normal cell lines
| Treatments | Cancer cell lines | Non-cancer cell lines | |||||
|---|---|---|---|---|---|---|---|
| SK-MEL | KB | BT-549 | SK-OV-3 | HL-60 | LLC-PK1 | Vero | |
| 1 | 14.83 | 29.66 | 23.31 | NA | NA | NC | NC |
| 2 | 3.88 | 10.87 | 10.87 | 27.95 | 18.17 | 24.84 | 38.82 |
| 3 | 2.02 | 5.90 | 3.57 | 6.21 | 17.32 | 27.95 | 15.53 |
| 4 | 12.88 | 37.88 | 37.88 | 22.73 | 2.57 | 18.18 | 15.91 |
| 5 | 5.26 | 10.96 | 28.51 | 21.93 | 4.29 | 21.93 | NC |
| 6 | 39.8 | NA | NA | NA | NA | 39.8 | NC |
| 7 | NA | NA | NA | NA | NA | NC | NC |
| 8 | NA | NA | NA | NA | NA | NC | NC |
| 9 | NA | NA | NA | NA | NA | NC | NC |
| Doxorubicin | 1.29 | 0.92 | 1.84 | 4.05 | — | 0.92 | 9.21 |
| Cisplatin | — | — | — | — | 1.46 | — | — |
NA or NC mean not active up to 40 μM.
Not tested.
SK-MEL: malignant melanoma, KB: oral epidermal carcinoma, BT-549: ductal breast carcinoma, SK-OV-3: ovary carcinoma, HL-60: human leukemia.
LLC-PK1: kidney epithelial, VERO: African green monkey kidney fibroblast.